Pharmaceutical - Markets & Marketing, Sanofi

Filter

Current filters:

Markets & MarketingSanofi

Popular Filters

1 to 25 of 53 results

Sanofi facing triple threat from Eli Lilly for diabetes treatment market space

Sanofi facing triple threat from Eli Lilly for diabetes treatment market space

26-06-2014

The imminent patent expiration of French pharma major Sanofi’s Lantus (insulin glargine) has opened…

BiosimilarsDiabetesdulaglutideEli LillyIDegLiraLantusLixiLanMarkets & MarketingNovo NordiskPharmaceuticalResearchSanofiToujeo

Rilutek patent expiry to cause negative growth in ALS treatment market by 2018

Rilutek patent expiry to cause negative growth in ALS treatment market by 2018

25-06-2014

The amyotrophic lateral sclerosis (ALS) treatment market value will decline from $64 million in 2013…

EuropeJapanMarkets & MarketingNeurologicalPatentsPharmaceuticalRilutekSanofiUSA

Sanofi Pasteur wins order for IPV from UNICEF, cutting price to $1 per dose

28-02-2014

Sanofi Pasteur, the vaccines division of French drug major Sanofi, says that UNICEF, the organization…

GlobalMarkets & MarketingPharmaceuticalPricingSanofiSanofi PasteurVaccines

Which place for orphan drugs in the strategy of pharma companies and payers?

27-02-2014

As the 7th Rare Disease Day will be held on February 28, ALCIMED, an innovation and new business consulting…

Markets & MarketingNovartisPharmaceuticalPricingRare diseasesResearchRocheSanofi

Modest growth expected for hepatitis B vaccine market

Modest growth expected for hepatitis B vaccine market

12-02-2014

The global hepatitis B virus (HBV) vaccine market value will experience modest growth over the coming…

Anti-viralsDynavax TechnologiesHeplisavHexyonMarkets & MarketingPharmaceuticalSanofiSanofi Pasteur MSDVaccines

Fast growth forecast for China’s colorectal cancer market

Fast growth forecast for China’s colorectal cancer market

13-12-2013

From 2012 to 2017, the colorectal cancer therapy market in China will grow at an annual rate of 9%, from…

AmgenAsia-PacificBayerIndiaMarkets & MarketingOncologyPharmaceuticalSanofiStivargaVectibixZaltrap

Sanofi to commercialize Vivus ED drug in Africa, Middle East, Turkey and CIS/Russia

Sanofi to commercialize Vivus ED drug in Africa, Middle East, Turkey and CIS/Russia

12-12-2013

US drugmaker Vivus has entered into a license and commercialization agreement with French pharma major…

avanafilEastern EuropeLicensingMarkets & MarketingMen's HealthPharmaceuticalRest of the WorldSanofiVivus

Novo Nordisk and Sanofi best positioned in diabetes market, says Morningstar

Novo Nordisk and Sanofi best positioned in diabetes market, says Morningstar

10-12-2013

Demographics favor the continued strong growth in the diabetes care market, and independent investment…

DiabetesEli LillyFinancialMarkets & MarketingNovo NordiskPharmaceuticalSanofi

What does the future hold for pharma?

What does the future hold for pharma?

22-11-2013

Here's our take on the week's top stories.

AstraZenecaBayerBiotechnologyCerulean PharmaMarkets & MarketingPharmaceuticalResearchSanofi

New products will grow atopic dermatitis market to $5.6 billion by 2022

New products will grow atopic dermatitis market to $5.6 billion by 2022

15-11-2013

Atopic dermatitis therapeutic sales in nine major global markets are forecast to increase from $3.9 billion…

Anacor PharmaceuticalsChinaDermatologicalsdupilumabEuropeIndiaMarkets & MarketingPharmaceuticalRegeneronSanofiUSA

Mixed US views on Gilenya, Aubagio and Tecfidera as breakthrough MS drugs

03-09-2013

More than half of surveyed neurologists consider US biotech firm Biogen Idec's (Nasdaq: BIIB) Tecfidera…

AubagioBiogen IdecGilenyaMarkets & MarketingNeurologicalNorth AmericaNovartisPharmaceuticalPricingSanofiTecfidera

China starts investigation of alleged bribery by Sanofi

12-08-2013

Following last week's whistleblower allegations that French drug major Sanofi (Euronext: SAN) had paid…

Asia-PacificLegalMarkets & MarketingPharmaceuticalPricingSanofi

Sanofi latest to be implicated Chinese bribery allegations

09-08-2013

In the wake of allegations that several multinational pharma companies have engaged in unlawful marketing…

Asia-PacificLegalLundbeckMarkets & MarketingNovo NordiskPharmaceuticalSanofi

New entrants to multiple sclerosis market will drive 10% pa growth through 2018

26-07-2013

The market for disease-modifying multiple sclerosis (MS) therapies will expand at an annual rate of 10%…

AbbVieAubagioBayerBiogen IdecBiotechnologydaclizumabGlobalLemtradaMarkets & MarketingNeurologicalocrelizumabPharmaceuticalRocheSanofiTecfidera

US and European Rxing decisions on metastatic colorectal cancer

15-07-2013

The effect of a therapy on overall survival and progression-free survival are attributes that most influence…

AvastinBayerEli LillyEuropeMarkets & MarketingNorth AmericaOncologyPharmaceuticalramucirumabRegeneronRocheSanofiStivargaZaltrap

Oncologists favor Avastin as first-line therapy for metastatic colorectal cancer

27-06-2013

For the treatment of metastatic colorectal cancer (mCRC), a majority of surveyed US oncologists surveyed…

AvastinBayerBiotechnologyBristol-Myers SquibbErbituxMarkets & MarketingMerck SeronoNorth AmericaOncologyPharmaceuticalRegeneronRocheSanofiStivargaZaltrap

Six months post launch, US prescribing trends for Xtandi

07-05-2013

At six months following launch of Xtandi (Astellas Pharma/Medivation's enzalutamide), surveyed urologists…

3MAstellas PharmaJevtanaJohnson & JohnsonMarkets & MarketingMedivationNorth AmericaOncologyPharmaceuticalSanofiXtandiZytiga

Sanofi plans acceleration of expansion into Ukraine this year

07-05-2013

French drug major Sanofi (Euronext: SAN) is considering expanding its presence in Ukraine this year,…

Cardio-vascularDiabetesEuropeMarkets & MarketingPharmaceuticalProductionSanofi

Growing US uptake of Genzyme's Aubagio at three months post-launch

07-03-2013

Some 34% of surveyed US neurologists have prescribed French drug major Sanofi (Euronext: SAN) subsidiary…

AubagioBiotechnologyGenzymeMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalSanofi

Amyotrophic lateral sclerosis sector lacks new and effective treatment options

06-02-2013

Amyotrophic Lateral Sclerosis (ALS) is the most common type of motor neuron disease (MND), yet the therapeutics…

ALS-02AvicenaMarkets & MarketingMitsubishi TanabeNeurologicalPharmaceuticalRadicutResearchRilutekSanofi

Genzyme says Lemtrada sBLA for MS accepted by FDA; reports on Aubagio

28-01-2013

French drug major Sanofi (Euronext: SAN) US biotech subsidiary Genzyme says that the US Food and Drug…

AubagioBiotechnologyGenzymeLemtradaMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalRegulationSanofi

Chinese diabetes market worth $2.2 billion, with over 50% accounted for by insulin

24-01-2013

Demand within the Chinese insulin market has grown at a fast pace in the past decade. Over the next five…

Asia-PacificDiabetesEli LillyMarkets & MarketingNovo NordiskPharmaceuticalSanofi

1 to 25 of 53 results

Back to top